← Leaderboards
Ralph Parchment
Leidos Biomedical Research, Inc.
$197,348,011
Attributed
$197,348,011
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $59.6M · FY2016–25$100M$75M$50M$25M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$197,348,011 · 2
By mechanism
N01$197,348,011 · 2
Top collaborators
No co-investigators on record.
Most similar at Leidos Biomedical Research, Inc.
Same institution · by research overlap
- David Heimbrook$2,362,140,846
- Leonard Freedman$1,216,107,431
- Ethan Dmitrovsky$597,515,186
- Gautam (george) Mitra$53,523,213
- John Otridge$12,071,178
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponsePharmaceutical PreparationsSiteClinical TrialsLaboratoriesBiological MarkersResistanceDivision Of Cancer Treatment And DiagnosisImmuneSpecimenReproducibilityPathway InteractionsEnrollmentData FilesGenotypeInstitute Of Medicine (U.S.)Authorization DocumentationAreaData WarehouseClinical ProtocolsContractsCharacteristicsClinical Data
Grant awards (13)
MD NET$41,960,680
N01 · FY2025 · CA · contact PI
MD NET$6,298,167
N01 · FY2024 · CA · contact PI
MD NET$33,472,471
N01 · FY2023 · CA · contact PI
CHARACTERIZING THE MECHANISM OF ACTION (MOA) OF INVESTIGATIONAL/APPROVED CANCER AGENTS$5,659,274
N01 · FY2023 · CA · contact PI
COMPARATIVE ONCOLOGY CLINICAL TRIALS$1,332,445
N01 · FY2020 · CA · contact PI
MD NET$54,828,827
N01 · FY2019 · CA · contact PI
MD NET: Pediatric$4,755,124
N01 · FY2019 · CA · contact PI
IGF::OT::IGF DCTD TUMOR TISSUE ACQUISITION$41,892
N01 · FY2018 · CA · contact PI
IGF::OT::IGF DISCOVERY OF NOVEL DRUG COMBINATIONS FOR CLINICAL DEVELOPMENT$41,192
N01 · FY2018 · CA · contact PI
IGF::OT::IGF High-plex Pharmacodynamic Biomarker Assay$25,266,647
N01 · FY2017 · CA · contact PI
Canine Immuno-Oncology$18,408,319
N01 · FY2017 · CA · contact PI
IGF::OT::IGF DISCOVERY OF NOVEL DRUG COMBINATIONS FOR CLINICAL DEVELOPMENT$2,700,568
N01 · FY2016 · CA · contact PI
IGF::OT::IGF DCTD TUMOR TISSUE ACQUISITION$2,582,405
N01 · FY2016 · CA · contact PI